📇 Rhumatologue · ST NAZAIRE · (44) · Libéral

MME MICHELE LEON-OILLIC

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Auteur de référence en rhumatologie
28 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
129.9 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 ST NAZAIRE (44)LibéralRPPS 10002587490

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

CABINET DU DR MICHELE LEON-OILLIC
18 BIS AVENUE PIERRE DE COUBERTIN, 44600 ST NAZAIRE
☎ 0240015221Activité de soin et de pharmacie

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Effectiveness of tezepelumab in severe asthma: A multicenter real-world study

European journal of internal medicine · 2026

📚 5 citations🎯 RCR 5.00🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Evidence-based management of intramural pregnancy: A comprehensive systematic review

European journal of obstetrics, gynecology, and reproductive biology · 2025

📚 2 citations

Effectiveness and safety of dual antiplatelet therapy in patients with minor ischemic stroke or transient ischemic attack and cancer: A secondary analysis of the READAPT study

European stroke journal · 2025

📚 1 citations🩺 Clinique🔓 Open Access

Lire l'abstract Crossref ↓

Abstract Introduction: Patients with ischemic stroke or transient ischemic attack (TIA) and cancer face unique risks of recurrent ischemic events and bleeding. It is unclear whether this increased risk is present even in patients with minor ischemic stroke or transient ischemic attack (TIA) receiving dual antiplatelet therapy (DAPT). This study aimed to evaluate the impact of cancer on the short-term outcomes after DAPT in patients with non-cardioembolic minor ischemic stroke or high-risk TIA. Patients and methods: This was a secondary analysis of the prospective multicentric READAPT study (NCT05476081), including patients with non-cardioembolic minor ischemic stroke (NIHSS ⩽ 5) or high-risk TIA (ABCD2 ⩾4) who initiated DAPT within 48 h of symptom onset. The primary effectiveness outcome was the 90-day risk of new ischemic stroke or other vascular events (TIA, myocardial infarction, death due to vascular causes). Secondary outcomes included 90-day mRS score distribution and all-cause mortality. The primary safety outcome was the 90-day risk of any bleeding, with secondary safety outcomes including 24-h hemorrhagic transformation. We used Inverse Probability Weighting to compare outcomes between patients with and without cancer. Results: From 2278 patients in the READAPT study cohort, we included 1561 patients (mean age 70.3 ± 11.7 years; 65.4% males), of whom 206 (13.2%) had cancer, categorized as either active (27.7%) or in remission (72.3%). After weighting, overall cancer patients had a higher risk of 90-day new ischemic stroke or other vascular events (weighted HR 1.78, 95% CI 1.20–2.63, p = 0.004) and worse 90-day mRS score distribution (OR 1.24, 95% CI 1.10–1.41, p &lt; 0.001) compared to patients without cancer. The 90-day risk of bleeding did not differ between cancer and no-cancer groups overall. When analyzing cancer subgroups, patients with active cancer had significantly higher risk of 90-day ischemic stroke or other vascular (weighted HR 2.75, 95% CI 1.70–4.45, p &lt; 0.001) and any bleeding (weighted HR 2.51, 95% CI 1.27–4.97, p = 0.008) events compared to no-cancer patients. In contrast, patients with cancer in remission had comparable risks to those without cancer. Furthermore, hematological malignancies were associated with a substantially higher risk of 90-day new ischemic stroke or other vascular events compared to solid tumors (weighted HR 8.15, 95% CI 5.06–13.14, p &lt; 0.001). Conclusions: Patients with minor ischemic stroke or high-risk TIA and active cancer have increased risk of ischemic and bleeding events after DAPT. Conversely, patients with cancer in remission have similar outcomes compared to those with no cancer.

Cookies & analyse de trafic

MME MICHELE LEON-OILLIC

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (28) — classées par pathologie

Transversal7

Épidémiologie & registres6

Revue générale6

Revue / méta-analyse4

Case report / série3

Vraie vie / RWE2

Essai clinique1

IRM ostéo-articulaire1

Pédiatrie1

Pharmacovigilance1

Recommandations1

SAPL1

Partager cette fiche